Ardelyx's third quarter 2026 revenue of $127.7M missed estimates while earnings significantly beat expectations

Ardelyx reported total revenue of $127.7 million, slightly missing the consensus estimate of $128.7 million. Despite the revenue miss, the company achieved near break-even results with a net loss of $0.7 million, or $0.00 per share, outperforming the anticipated $0.03 loss per share. Commercial progress remains driven by the tenapanor franchise, specifically IBSRELA, which saw strong double-digit growth.

Key Highlights

• IBSRELA net product sales grew 23% year-over-year to $96.3 million, supported by an expansion in total prescribing physicians and prescription volume.
• Management reiterated full-year 2026 IBSRELA revenue guidance of $350 million to $370 million and total operating expenses below $500 million.
• The Phase 3 ACCEL trial for chronic idiopathic constipation (CIC) completed enrollment ahead of schedule, with topline data expected in the second half of 2027.